G-CSF (Filgrastim) as an Adjunct to MOPP/ABVD Therapy in Hodgkin's Disease

References

• DeVita V T, Hellman S, Jaffe E. Hodgkin's disease. Cancer: Principles and practice of oncology, V T DeVita, S Hellman, S A Rosenberg. JB Lippincott Co, Philadelphia 1993; 1819–58
   Google Scholar
• Urba W J, Longo D L. Hodgkin's disease. N Engl J Med 1992; 326: 678–87
   PubMed Web of Science ®Google Scholar
• Carde P, MacKintosh F R, Rosenberg S A. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol 1983; 1: 146–53
   PubMed Web of Science ®Google Scholar
• Longo D L, Young R C, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986; 4: 1295–306
   PubMed Web of Science ®Google Scholar
• DeVita V T, Hubbard S M, Longo D L. The chemotherapy of lymphomas: Looking back, moving forward—The Richard and Hinda Rosenthal foundation award lecture. Cancer Res 1987; 47: 5810–24
   PubMed Web of Science ®Google Scholar
• Gobbi P G, Cavalli C, Rossi A, et al. The role of dose and rate of administration of MOPP drugs in 97 retrospective Hodgkin's patients. Haematologica 1987; 72: 523–8
   PubMed Web of Science ®Google Scholar
• Lagarde P, Bonichon F, Eghbali H, et al. Influence of dose intensity and density on therapeutic and toxic effects in Hodgkin's disease. Br J Cancer 1989; 59: 645–9
   PubMed Web of Science ®Google Scholar
• van Rijswijk R EN, Haanen C, Dekker A W, et al. Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. J Clin Oncol 1989; 7: 1776–82
   PubMed Web of Science ®Google Scholar
• Pettengell R, Gurney H, Radford J A, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992; 80: 1430–6
   PubMed Web of Science ®Google Scholar
• Harmenberg J, Höglund M, Hellström-Lindberg E. G- and GM-CSF in oncology and oncological haematology. Eur J Haematol 1994; 52: 1–28
   PubMed Web of Science ®Google Scholar
• Carbone P P, Kaplan H S, Musshof K, et al. Report of the committee on Hodgkin's disease staging. Cancer Res 1971; 31: 1960–1
   Google Scholar
• Glimelius B, Enblad G, Kälkner M, et al. Treatment of Hodgkin's disease: The Swedish National Care programme experience. Leuk & Lymphoma 1996; 21: 71–8
   PubMed Web of Science ®Google Scholar
• Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281–8
   PubMed Web of Science ®Google Scholar
• Blayney D W, Bosserman L D, Vakil M. Dose intense MOPP/ABV with prophylactic filgrastim (G-CSF) treatment of advanced Hodgkin's disease (HD): a pilot study (Abstract). Blood 1994; 84: 638
   PubMed Web of Science ®Google Scholar
• Silvestri F, Fanin R, Velisig M, et al. The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease. Tumori 1994; 80: 53–8
   Web of Science ®Google Scholar
• Raybon K, Schroeder M, Allerton J. Increased dose intensity (DI) of doxorubicin and vinblastine during ABVD therapy of Hodgkin's lymphoma with the use of granulocyte colony stimulating factor (GCSF) (Abstract). Blood 1995; 86: 821A, Suppl 1
   Google Scholar
• Dunlop D J, Anderson S, Paul J, et al. Filgrastim as an adjunct to combination chemotherapy in Hodgkin's disease (Abstract). Br J Cancer 1994; 69: 11, Suppl 21
   Google Scholar
• Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164–70
   PubMed Web of Science ®Google Scholar
• Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993; 29A: 319–24
   PubMed Web of Science ®Google Scholar
• Matthews J H. Pulmonary toxicity of ABVD chemotherapy and G-CFS in Hodkgins disease: possible synergy. Lancet 1993; 342: 988
   PubMed Web of Science ®Google Scholar
• Lei K IK, Leung W T, Johnson P J. Serious pulmonary complications in patients receiving recombinant granulocyte colony-stimulating factor during BACOP chemotherapy for aggressive non-Hodgkin's lymphoma. Br J Cancer 1994; 70: 1009–13
   PubMed Web of Science ®Google Scholar
• Bastion Y, Reyes F, Bosly A, et al. Possible toxicity with the association of G-CSF and bleomycin. Lancet 1994; 343: 1221–2
   PubMed Web of Science ®Google Scholar